Understanding heterogeneity in response to antidiabetes treatment: A Post Hoc analysis using SIDES, a subgroup identification algorithm

Journal of Diabetes Science and Technology

Volumn 7, Issue 2, 2013, Pages 420-430

  Hardin, Dana S ^a   Rohwer, Rachelle D ^a   Curtis, Bradley H ^a   Zagar, Anthony ^a   Chen, Lei ^a   Boye, Kristina S ^a   Jiang, Honghua H ^a   Lipkovich, Ilya A ^b  

^a ELI LILLY AND COMPANY   (United States)

^b IQVIA   (United States)

Author keywords

Differential treatment response; Heterogeneity; Insulin; Predictors of treatment effect; Subgroup identification; Subgroup identification based on differential effect search

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ANTIDIABETIC AGENT; GLARGINE; LONG ACTING INSULIN;

ADULT; AGED; ALGORITHM; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SUBGROUP IDENTIFICATION BASED ON DIFFERENTIAL EFFECT SEARCH; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY; CONTROLLED CLINICAL TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANALYSIS OF VARIANCE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84891397589     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681300700219     Document Type: Article

References (24)

1. World Health Organization. Diabetes. Fact sheet. No. 312. http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed April 12, 2012.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
3. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378(9785):31-40.
4. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
5. Shomali ME. Practical applications of therapy with a glucagon-like peptide-1 receptor agonist. J Fam Pract. 2009;58(9 Suppl Treating):S35-43.
6. Cantrell RA, Alatorre CI, Davis EJ, Zarotsky V, Le Nestour E, Carter GC, Goetz I, Paczkowski R, Sierra-Johnson J. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab. 2010;12(10):845-57.
7. Greenfield S, Kravitz R, Duan N, Kaplan SH. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med. 2007;120(4 Suppl 1):S3-9. (Pubitemid 46497038)
8. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82(4):661-87. (Pubitemid 40143102)
9. Ruberg SJ, Chen L, Wang Y. The mean does not mean as much anymore: finding sub-groups for tailored therapeutics. Clin Trials. 2010;7(5):574-83.
10. Fahrbach J, Jacober S, Jiang H, Martin S. The DURABLE trial study design: comparing the safety, eficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Technol. 2008;2(5):831-8.
11. Buse JB, Wolfenbuttel BH, Herman WH, Shemonsky NK, Jiang HH, Fahrbach JL, Scism-Bacon JL, Martin SA. DURAbility of basal versus lispro mix 75/25 insulin eficacy (DURABLE) trial 24-week results: safety and eficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32(6):1007-13.
12. Herman WH, Dungan KM, Wolfenbuttel BH, Buse JB, Fahrbach JL, Jiang H, Martin S. Racial and ethnic diferences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(5):1689-94.
13. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999.
14. Lipkovich I, Dmitrienko A, Denne J, Enas G. Subgroup identification based on differential effect search - a recursive partitioning method for establishing response to treatment in patient subpopulations. Stat Med. 2011;30(21):2601-21.
15. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and regression trees. New York: Chapman & Hall/CRC; 1984.
16. Owen V, Seetho I, Idris I. Predictors of responders to insulin therapy at 1 year among adults with type 2 diabetes. Diabetes Obes Metab. 2010;12(10):865-70.
17. Food and Drug Administration. Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance. February 2008. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071624.pdf. Accessed February 20, 2013.
18. De Castro JM. Age-related changes in spontaneous food intake and hunger in humans. Appetite. 1993;21(3):255-72. (Pubitemid 24032271)
19. Cnop M, Igoillo-Esteve M, Hughes SJ, Walker JN, Cnop I, Clark A. Longevity of human islet α- and β-cells. Diabetes Obes Metab. 2011;13 Suppl 1:39-46.
20. Harris MI. Summary. In: Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, eds. Diabetes in America. 2nd ed. NIH Publication No. 95-01468. Bethesda: National Diabetes Data Group; 1995, 12.
21. Harris MI, Cowie CC, Gu K, Francis ME, Flegal K, Eberhardt MS. Higher fasting insulin but lower fasting C-peptide levels in African Americans in the US population. Diabetes Metab Res Rev. 2002;18(2):149-55. (Pubitemid 34467305)
22. Pettitt DJ, Moll PP, Knowler WC, Mott DM, Nelson RG, Saad MF, Bennett PH, Kottke BA. Insulinemia in children at low and high risk of NIDDM. Diabetes Care. 1993;16(4):608-15. (Pubitemid 23097210)
23. Arslanian SA, Saad R, Lewy V, Danadian K, Janosky J. Hyperinsulinemia in african-american children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. Diabetes. 2002;51(10):3014-9.
24. Corkey BE. Diabetes: have we got it all wrong? Insulin hypersecretion and food additives: cause of obesity and diabetes? Diabetes Care. 2012;35(12):2432-7.